Medical devices, healthcare technology and the business of care
510(k) clearance · K262451

Arthrex DynaNite Staples

ARTHREX, INC. · Decision date Sep 1, 2026

MEDTECHLEDGER EXPLANATIONK262451

What did the FDA decide?

FDA's September 1, 2026 decision letter records Arthrex DynaNite Staples (K262451) as substantially equivalent (SESE) under 21 CFR 888.3030, Class II, product code JDR, with the Orthopedic review panel. The submission was dated July 16, 2026 and received July 17, 2026; the applicant is Arthrex, Inc. of Naples, Florida. Substantial equivalence is a clearance to market, not premarket approval.

The letter states equivalence to legally marketed predicate devices for the indications for use in the enclosure, but the supplied excerpts do not include that enclosure, so the specific indications, device materials, sizes and any predicate identified in the submission remain unknown. FDA also notes the determination does not establish compliance with other statutory or regulatory requirements, including QMSR obligations. No clinical or performance data are available in the provided text.

The public record lists the review as a Traditional 510(k), not third-party reviewed, not a combination product, and without an authorized predetermined change control plan. The page's last-updated date of October 26, 2026 is later than the decision date and is not explained in the public information.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Orthopedic
Decision date
Sep 1, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K262451
Regulatory pathway
510(k) premarket notification
Applicant
ARTHREX, INC.
Product code
JDR
Decision code
SESE
Decision date
Sep 1, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Staple, Fixation, Bone.

Applicant
Arthrex, Inc.
Product code
JDR
FDA device class
2

FDA decision timeline

  1. K262451 received

    Application receipt date recorded by FDA.

  2. K262451 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Arthrex, Inc.

Headquarters
Not reported
Brand website
arthrex.com
FDA applicant address
Naples, FL

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records